Document Type

Article

Publication Date

7-21-2024

Comments

This article is the author's final published version in Scientific Reports, Volume 14, 2024, Article number 16766.

The published version is available at https://doi.org/10.1038/s41598-024-55375-0. Copyright © The Author(s) 2024.

Abstract

The tumor microenvironment (TME) plays a pivotal role in the onset, progression, and treatment response of cancer. Among the various components of the TME, cancer-associated fibroblasts (CAFs) are key regulators of both immune and non-immune cellular functions. Leveraging single-cell RNA sequencing (scRNA) data, we have uncovered previously hidden and promising roles within this specific CAF subgroup, paving the way for its clinical application. However, several critical questions persist, primarily stemming from the heterogeneous nature of CAFs and the use of different fibroblast markers in various sample analyses, causing confusion and hindrance in their clinical implementation. In this groundbreaking study, we have systematically screened multiple databases to identify the most robust marker for distinguishing CAFs in lung cancer, with a particular focus on their potential use in early diagnosis, staging, and treatment response evaluation. Our investigation revealed that COL1A1, COL1A2, FAP, and PDGFRA are effective markers for characterizing CAF subgroups in most lung adenocarcinoma datasets. Through comprehensive analysis of treatment responses, we determined that COL1A1 stands out as the most effective indicator among all CAF markers. COL1A1 not only deciphers the TME signatures related to CAFs but also demonstrates a highly sensitive and specific correlation with treatment responses and multiple survival outcomes. For the first time, we have unveiled the distinct roles played by clusters of CAF markers in differentiating various TME groups. Our findings confirm the sensitive and unique contributions of CAFs to the responses of multiple lung cancer therapies. These insights significantly enhance our understanding of TME functions and drive the translational application of extensive scRNA sequence results. COL1A1 emerges as the most sensitive and specific marker for defining CAF subgroups in scRNA analysis. The CAF ratios represented by COL1A1 can potentially serve as a reliable predictor of treatment responses in clinical practice, thus providing valuable insights into the influential roles of TME components. This research marks a crucial step forward in revolutionizing our approach to cancer diagnosis and treatment.

Creative Commons License

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.

Additional Files
Supplementary Information.pdf (655 kB)
Supplementary Information
Supplementary Figure S1.tif (5951 kB)
Supplementary Figure S1
Supplementary Figure S2.tif (3292 kB)
Supplementary Figure S2
Supplementary Figure S3.tif (1367 kB)
Supplementary Figure S3
Supplementary Figure S4.tif (3610 kB)
Supplementary Figure S4
Supplementary Figure S5.tif (1348 kB)
Supplementary Figure S5
Supplementary Figure S6.tif (1988 kB)
Supplementary Figure S6
Supplementary Figure S7.tif (1590 kB)
Supplementary Figure S7
Supplementary Figure S8.tif (998 kB)
Supplementary Figure S8
Supplementary Figure S9.tif (984 kB)
Supplementary Figure S9
Supplementary Figure S10.tif (1432 kB)
Supplementary Figure S10
Supplementary Legends.docx (17 kB)
Supplementary Legends

PubMed ID

39034310

Language

English

Download

Share

COinS